5-蒽基肼 | 25975-59-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 5-蒽基肼
• 中文别名: 雄甾-5-烯二醇
• 英文名称: 3β,17β-dihydroxy-19-norandrost-5-ene
• 英文别名: 19-nor-androst-5-ene-3β,17β-diol；5-estrene-3β,17β-diol；19-norandrostenediol；estr-5-ene-3β,17β-diol；Oestr-5-en-3β,17β-diol；19-nor-androst-5-en-3β,17β-diol；19-Nor-5-androstenediol；(3S,8R,9S,10R,13S,14S,17S)-13-methyl-1,2,3,4,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,17-diol
• CAS: 25975-59-1
• 化学式: C₁₈H₂₈O₂
• 分子量: 276.419
• InChiKey: VVUQRXPUVKXAIO-XFUVECHXSA-N

物化性质

• 熔点：
  152-157 °C(Solv: ethanol, 95% (64-17-5))
• 沸点：
  429.2±45.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)
• 溶解度：
  氯仿（极少量，超声处理）、甲醇（少量溶解）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-蒽基肼 在 吡啶 、 4-二甲氨基吡啶 、 溴 、 potassium acetate 、 potassium carbonate 、 溶剂黄146 、 pyridinium chlorochromate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 水 为溶剂， 反应 37.17h， 生成 雌二醇
  参考文献：
  名称：

  First synthesis of a steroid containing an unstable 19-nor-androsta-1,5-dien-3-one system

  摘要：

  Mechanisms involved in the maintenance of human pregnancy and initiation of labour are poorly defined. A novel steroid hormone named estradienolone (ED), and having an unusual 19-nor-androsta- 1,5-dien-3-one system, was previously reported. However, ED is scarcely available from urine, placenta and blood of pregnant women. For this reason, we have synthesized ED in order to verify its proposed structure. Although a 1,5-dien-3-one system had already been described for a C19-steroid (androstane) nucleus (no possible aromatization), the synthesis of the 19-nor-analogue is a major challenge because this system is very sensitive to aromatization. We now describe the successful construction and characterization of this unstable system. Starting from nortestosterone, the synthesis of 17 beta-hydroxy-19-nor-androsta-1,5-dien-3-one (1) is based on a protection of the 5,6-double bond, the introduction of the second 1,2-double bond, the careful recovery of the exo double bond and a final regioselective oxidation or reduction. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2006.02.063
• 作为产物：
  描述：

  诺龙 在 lithium aluminium tetrahydride 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 正丁醇 为溶剂， 反应 32.0h， 生成 5-蒽基肼
  参考文献：
  名称：

  [EN] PROGESTERONE RECEPTOR ANTAGONISTS AND USES THEREOF
  [FR] ANTAGONISTES DU RÉCEPTEUR DE LA PROGESTÉRONE ET UTILISATIONS CORRESPONDANTES

  摘要：

  本发明涉及一种化合物，其化学式为(I)，用作孕激素受体拮抗剂，特别是用于预防和/或治疗癌症或子宫病变。

  公开号：

  WO2011138460A1

文献信息

• FLUORESCENCE BASED DETECTION OF SUBSTANCES
  申请人：Russell David

  公开号：US20090230322A1

  公开（公告）日：2009-09-17

  A method for the fluorescent detection of a substance, the method comprising providing particles comprising a metal or a metal oxide core, wherein one or more optionally fluorescently tagged antibodies or human specific peptide nucleic acid (PNA) oligomers for binding to a substance is/are bound, directly or indirectly, to the surface of the metal or metal oxide; contacting a substrate, which may or may not have the substance on its surface, with the particles for a time sufficient to allow the antibody/PNA oligomer to bind with the substance; removing those particles which have not bound to the substrate; if the antibodies or PNA oligomers are not fluorescently tagged, contacting the substrate with one or more fluorophores that selectively bind with the antibody and/or substance, then optionally washing the substrate to remove unbound fluorophores; and illuminating the substrate with appropriate radiation to show the fluorophores on the substrate.

  一种用于荧光检测物质的方法，该方法包括提供含有金属或金属氧化核的颗粒，其中一种或多种可选择性地荧光标记的抗体或人特异性肽核酸（PNA）寡聚体，用于结合到物质上，直接或间接地结合到金属或金属氧化物的表面；将可能在其表面具有或不具有该物质的基质与这些颗粒接触一段时间，以充分允许抗体/PNA寡聚体与该物质结合；移除那些未与基质结合的颗粒；如果抗体或PNA寡聚体未被荧光标记，则将基质与一种或多种能特异性结合抗体和/或物质的荧光剂接触，然后可选择地清洗基质以去除未结合的荧光剂；并用适当的辐射照射基质以显示基质上的荧光剂。
• [EN] COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES PERMETTANT DE TRAITER LES TROUBLES DU SNC
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2019126761A1

  公开（公告）日：2019-06-27

  Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein t, R7, R3, R9, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R17a, R17b, R18a, R18b, R19a, R19b, R5a, R5b, R8 and R13 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

  本文提供了一种式（I-I）的化合物或其药用可接受盐，其中t、R7、R3、R9、R6a、R6b、R11a、R11b、R15a、R15b、R16a、R16b、R17a、R17b、R18a、R18b、R19a、R19b、R5a、R5b、R8和R13在此定义。本文还提供了包括式（I-I）化合物的药物组合物以及使用这些化合物的方法，例如在治疗与中枢神经系统相关的疾病中。
• [EN] AZA-, OXA AND THIA-PREGNAN-20-ONE-3.ALPHA.-OL COMPOUNDS FOR USE IN TREATING CNS DISORDERS<br/>[FR] COMPOSÉS AZA-, OXA ET THIA-PREGNAN-20-ONE-3.ALPHA.-OL S'UTILISANT DANS LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2019140272A1

  公开（公告）日：2019-07-18

  Provided herein is a compound of Formula (I-I), or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

  本文提供了一种公式(I-I)的化合物，或其药学上可接受的盐，其中变量在此定义。本文还提供了包含公式(I-I)的化合物的药物组合物，以及使用该化合物的方法，例如用于治疗中枢神经系统相关疾病。
• Bone anabolic compounds and methods of use
  申请人：——

  公开号：US20030119800A1

  公开（公告）日：2003-06-26

  A variety of bone anabolic compounds are useful for maintaining and/or increasing bone mass, density, and/or strength in mammals. Preferred compounds enhance bone anabolic activity while minimizing or eliminating undesirable feminizing or masculinizing effects.

  多种骨骼增生化合物对于维持和/或增加哺乳动物的骨量、密度和/或强度是有用的。优选的化合物增强骨骼增生活性，同时最小化或消除不良的女性化或男性化效果。
• Radioimmunoassay agents
  申请人：The Upjohn Company

  公开号：US04013688A1

  公开（公告）日：1977-03-22

  Novel steroid derivatives containing a tyrosine ester amide group linked to an 11-hydroxysteroid alkylene dicarboxylic hemi-ester are described, suitable for iodination with radioactive iodine, useful in radioimmunoassay.

  本文描述了一种含有酪氨酸酯酰胺基团的新型类固醇衍生物，该基团与11-羟基类固醇烷二羧酸半酯相连，适用于与放射性碘进行碘化反应，用于放射免疫测定中。